- Chemomab Therapeutics (CMMB, Financial) to present clinical data on nebokitug (CM-101) for PSC treatment at three major scientific conferences in 2025.
- Key findings show CM-101's safety, tolerability, and improvement in inflammation, fibrosis, and cholestasis biomarkers.
- Presentations by Dr. Paul Pockros, CEO Adi Mor, and Prof. Douglas Thorburn at DDW25, EASL 2025, and BSG LIVE'25 respectively.
Chemomab Therapeutics (CMMB) has announced that it will showcase clinical data on nebokitug (CM-101), aimed at treating primary sclerosing cholangitis (PSC), at three prestigious scientific conferences in 2025. The presentations will feature data focused on CM-101's impact on inflammation, fibrosis, and cholestasis in PSC patients, with a particular emphasis on its safety and tolerability profile.
The first of these presentations will occur at Digestive Disease Week 2025 (DDW25) in San Diego from May 3-6, where Dr. Paul Pockros will deliver an oral presentation on the findings. The subsequent presentations are scheduled for the Annual Congress of the European Association for the Study of the Liver (EASL 2025) in Amsterdam from May 7-10. Here, CEO Adi Mor will present two posters discussing the drug's pharmacokinetics, pharmacodynamics, and proteomic profile alterations.
Lastly, results from the SPRING Study will be shared during the BSG LIVE'25 event in Glasgow across June 23-26 by Prof. Douglas Thorburn. These findings underscore the potential of CM-101 as a novel therapeutic agent in managing primary sclerosing cholangitis, with nebokitug having already received FDA and EMA Orphan Drug and FDA Fast Track designations, highlighting its promising role in addressing significant unmet medical needs.
